Nicholas Investment Partners, LP Uni Qure N.V. Transaction History

Nicholas Investment Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$35.98 - $47.66 $1.13 Million - $1.49 Million	-31,284 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$45.06 - $67.74 $1.36 Million - $2.04 Million	-30,118 Reduced 49.05%	31,284 $1.41 Million
Q1 2020 May 13, 2020	SELL	$40.01 - $73.97 $1.57 Million - $2.9 Million	-39,252 Reduced 39.0%	61,402 $2.91 Million
Q4 2019 Feb 13, 2020	BUY	$37.13 - $74.62 $64,791 - $130,211	1,745 Added 1.76%	100,654 $7.21 Million
Q3 2019 Nov 13, 2019	BUY	$39.36 - $76.8 $457,796 - $893,260	11,631 Added 13.33%	98,909 $3.89 Million
Q2 2019 Aug 09, 2019	SELL	$52.76 - $82.19 $22,370 - $34,848	-424 Reduced 0.48%	87,278 $6.82 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $2.4 Million - $6 Million	87,702 New	87,702 $5.23 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.